Pulmonary fibrosis clinical trials

Explore recruiting pulmonary fibrosis clinical trials.

Recruiting pulmonary fibrosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pulmonary fibrosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)

France, Germany, Italy, Spain, Poland, Netherlands +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis (RENEW)

Germany, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)

Germany, Netherlands, Italy, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia - A prospective two-armed, phase II clinical multicentre randomized, placebo-controlled (2:1), blinded with open-label extension trial (TEFIBEOS)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Netherlands, Greece, Slovenia, Germany, Hungary, France +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial evaluating the efficacy and safety of 2 doses of buloxibutid over 52 weeks in people with idiopathic pulmonary fibrosis.

Austria, Germany, Greece, Poland, Belgium, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Pulmonary fibrosis trials by city

Pulmonary fibrosis in Toronto Pulmonary fibrosis in Vancouver Pulmonary fibrosis in Montreal Pulmonary fibrosis in Calgary Pulmonary fibrosis in Edmonton Pulmonary fibrosis in Ottawa Pulmonary fibrosis in Winnipeg Pulmonary fibrosis in Quebec City Pulmonary fibrosis in Hamilton Pulmonary fibrosis in Kitchener Pulmonary fibrosis in London Pulmonary fibrosis in Halifax Pulmonary fibrosis in New York Pulmonary fibrosis in Los Angeles Pulmonary fibrosis in Chicago Pulmonary fibrosis in Houston

Other conditions

Schizophrenia PTSD OCD ADHD Insomnia Postpartum depression Alcohol use disorder Substance use disorder COPD Asthma Long COVID Cystic fibrosis Sleep apnea Chronic cough Crohn's disease Ulcerative colitis Irritable bowel syndrome Celiac disease GERD Eosinophilic esophagitis Gastroparesis Rheumatoid arthritis Lupus Psoriatic arthritis